

Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs

Meg K Tully¹, Saber Dini¹, Jennifer A Flegg², James S McCarthy^{3,4,5}, David J Price^{1,3,†}, Julie A Simpson^{1,6†,*}

¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

²School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia

³Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia

⁴Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia

⁵Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

⁶Nuffield Department of Medicine, University of Oxford, Oxford, UK

† Co-senior authors

* Corresponding author: julieas@unimelb.edu.au

Key words: pharmacokinetic-pharmacodynamic modelling, antimalarial, Bayesian methods, simulation

CONFLICT OF INTEREST

All authors declared no competing interests for this work.

FUNDING

This work was supported by the Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grants (#1196068) to JAS and (#2016396) to JSM, the Australian Centre for Research Excellence in Malaria Elimination (#2024622) and a NHMRC Synergy Grant (#2018654).

1 ***Abstract***

2 The rise of multidrug resistant malaria requires accelerated development of novel an-
3 timalarial drugs. Pharmacokinetic-pharmacodynamic (PK-PD) models relate blood
4 antimalarial drug concentrations with the parasite-time profile to inform dosing regi-
5 ments. We performed a simulation study to assess the utility of a Bayesian hierarchical
6 mechanistic PK-PD model for predicting parasite-time profiles for a Phase 2 study of
7 a new antimalarial drug, cipargamin.

8 We simulated cipargamin concentration- and malaria parasite-profiles based on a
9 Phase 2 study of 8 volunteers who received cipargamin 7 days after inoculation with
10 malaria parasites. The cipargamin profiles were generated from a 2-compartment
11 PK model and parasite profiles from a previously published biologically informed PD
12 model. One-thousand PK-PD datasets of 8 patients were simulated, following the
13 sampling intervals of the Phase 2 study. The mechanistic PK-PD model was incor-
14 porated in a Bayesian hierarchical framework and the parameters estimated.

15 Population PK model parameters describing absorption, distribution and clear-
16 ance were estimated with minimal bias (mean relative bias ranged from 1.7 to 8.4%).
17 The PD model was fitted to the parasitaemia profiles in each simulated dataset using
18 the estimated PK parameters. Posterior predictive checks demonstrate that our PK-
19 PD model successfully captures both the pre- and post-treatment simulated PD pro-
20 files. The bias of the estimated population average PD parameters was low-moderate
21 in magnitude.

22 This simulation study demonstrates the viability of our PK-PD model to predict
23 parasitological outcomes in Phase 2 volunteer infection studies. This work will in-
24 form the dose-effect relationship of cipargamin, guiding decisions on dosing regimens
25 to evaluate in Phase 3 trials.

1 Introduction

Almost 40% of the global population live in malaria endemic areas, with an estimated 249 million clinical cases in 2022, and over 608,000 deaths [1]. Following a significant fall in the global malaria burden between 2005 and 2015, the estimated number of malaria cases and deaths has begun to rise over recent years [1]. The availability of effective antimalarial drugs is key to reducing the burden of morbidity and mortality attributable to malaria.

Artemisinin-based combination therapies (ACTs), comprised of a highly potent and rapid-acting artemisinin-derivative with a longer-acting partner drug, are the current first-line treatment for *Plasmodium falciparum* malaria infection. However, partial resistance to artemisinins is now widespread across Southeast Asia [2] and more recently, has emerged *de novo* in some African countries [3, 4], South America [5] and Papua New Guinea [6]. Moreover, resistance to the partner drugs used in ACTs, such as piperazine, has also been detected in Southeast Asia [7], resulting in treatment failures. New antimalarial drugs are urgently needed.

Drug development is a resource-heavy, expensive and time-consuming process, with only approximately 10% of drugs tested in Phase 1 trials ultimately gaining approval [8]. The journey from early phase clinical trials to Phase 3 clinical trials in patients, to then drug registration, can take many years [9]. Cipargamin is a promising candidate antimalarial drug that has transitioned from early phase studies [10] to Phase 2 clinical trials of adult patients with falciparum malaria [11, 12]. In particular, it is a rapidly acting parenteral agent with promise to replace artemisinin [13]. McCarthy and colleagues investigated the efficacy of cipargamin in a Phase 2 clinical trial [14] in 8 healthy volunteer patients who were experimentally infected with malaria and seven days later administered a low dose (10mg) of cipargamin.

51 These human challenge studies, also known as volunteer infection studies, involve
52 purposeful infection of healthy volunteers in a controlled environment, and produce
53 rich data on both parasite and drug concentrations through frequent sampling [15].
54 Given the ethical considerations of infecting healthy volunteers, it is imperative that
55 the maximum information possible is obtained from these data, in order to guide
56 selection of dosing regimens investigated for future Phase 2 and 3 studies. Statistical
57 methods that are tailored to generating inferences from these valuable data are thus
58 required. Pharmacokinetic-Pharmacodynamic (PK-PD) modelling is a typical frame-
59 work used for such analyses. These models integrate the PK model, that describes
60 the drug concentration over time, with a PD model that characterises the drug's ef-
61 fect on the parasite population. Ideally, a PK-PD model should capture key elements
62 of the underlying biological system, whilst remaining sufficiently simple for practical
63 estimation and interpretation of key parameters [16].

64 In this study we assessed an adaptation of an existing mechanistic Bayesian hi-
65 erarchical PK-PD model developed by Dini *et al.* [17], which captures the life cycle
66 of the parasite within the red blood cell. Within a simulation-estimation framework,
67 we investigated how precisely and accurately this model was able to recover the PK
68 and PD parameters. The simulation study is based on data from the Phase 2 clinical
69 study of cipargamin [14].

70 **2 Results**

71 A detailed description of the PK model, PD model, the Bayesian inference frame-
72 work, and simulation study setup, including all model parameters, are provided in
73 the Methods section. Definitions of the PK and PD model parameters are given in
74 Tables 1 and 2 with a study overview diagram provided in Figure 1.

75

76 **Pharmacokinetic Model**

77 Cipargamin concentrations were simulated using a 2-compartment PK model with
78 first-order absorption, based on the estimated PK parameters and between-individual
79 variability from the analysis of the Phase 2 trial PK data [14] (Table 3). A total
80 of 1000 simulated datasets were generated, each dataset included the PK and PD
81 profiles of 8 patients, incorporating between- and within-individual variability. The
82 simulated 8-patient PK datasets provided a good visual match to the trial data from
83 McCarthy *et al.* [14] (Figure S1). The PK model was incorporated into a Bayesian
84 hierarchical framework, and fitted to each of the 1000 simulated datasets, restricting
85 data to the cipargamin concentrations which correspond to the sampling times of
86 the original Phase 2 trial (1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours
87 post-treatment), and the posterior median estimate of each population PK parameter
88 obtained. To evaluate how accurately this model can estimate PK parameters, we
89 calculated the difference (absolute and relative bias) between the posterior median
90 estimate of the population-level PK parameter, and the value used to simulate the
91 data (*i.e.*, the ‘true’ value). Table 4 shows the ‘true’ PK parameter values used to
92 simulate the data, the mean, 2.5- and 97.5-percentiles (herein, 95% intervals) across
93 the 1000 posterior median estimates associated with each simulation, and the bias
94 (absolute and relative) in these posterior median estimates. The population-level

95 PK parameters were reliably estimated, with the magnitude of relative bias ranging
96 from 1.7% to 8.4%, comparing the mean of the posterior median estimates to the
97 ‘true’ value. To contextualise the bias in these estimates, we compared the PK profile
98 created by the ‘true’ population parameters to the PK profiles generated at the 1000
99 posterior median parameter estimates (Figure 2). This figure demonstrates that the
100 average PK profiles for cipargamin are captured well across all simulations.

101 The population-level PK parameter least accurately estimated by the model was
102 the absorption parameter, k_a , with a mean relative bias of 8.4% [95% intervals (-9.7%,
103 32%)]. The PK profiles exhibit a short and sharp rise in drug concentration upon
104 administration, during which absorption may be estimated, however the availability of
105 only 1 to 2 observations from this period impedes the estimation of the k_a parameter.
106 When the drug concentration profiles produced from the ‘actual’ and ‘estimated’ PK
107 parameters were compared (Figure 2), it is clear that the discrepancies between the
108 absorption parameter values do not materially impact the cipargamin concentrations
109 during the distribution and elimination phases.

110 To investigate how well this framework can recover model parameters for a sin-
111 gle experiment, we show an example of the posterior samples compared to the ‘true’
112 value in Figure 3. These show that the true parameter values are contained within
113 the range of posterior samples for each parameter, considering pairwise correlations.
114 FigureS4 shows the posterior predictive pharmacokinetic profiles for each of the eight
115 patients in a single experiment, again demonstrating that the posterior model fit pro-
116 vides an accurate characterisation of the pharmacokinetic profile.

117

118 **Pharmacodynamic Model**

119 For each of the above simulated 1000 datasets, the 8 individual cipargamin concentration-
120 time profiles were used to simulate 8 parasite count profiles. These parasitaemia pro-

121 files were simulated for the initial 7 days of parasite growth post-inoculation. The
122 simulated cipargamin concentration profiles were then used to simulate drug-induced
123 killing of the parasites over the next two days, post cipargamin administration on day
124 7. The PD model simulated the number of parasites aged 1 to 40 hours at each time
125 point, and data for fitting the model was again restricted to the sampling times of the
126 original study (72, 96, 108, 120, 132, 144, 156, 168, 172, 176, 180, 184, 192, 198, 204,
127 216, 228, 240, 264 and 288 hours post-innoculation). We assumed cipargamin had an
128 immediate effect on the parasite, and that the concentration-effect relationship fol-
129 lowed Michaelis-Menten kinetics. The PD parameter values and between-individual
130 variability selected for generation of the PD profiles are provided in Table 5. The
131 1000 simulated PD datasets provided a good visual match to the parasitaemia data
132 from McCarthy *et al.* [14] (Figure S5).

133 Table 6 shows the ‘true’ PD parameter values, the mean and 95% intervals across
134 the 1000 posterior median estimates, and the absolute and relative bias in the poste-
135 rior median estimates for each PD parameter. The magnitude of relative bias for the
136 posterior median estimates of the seven PD parameters varied between 1% and 53%.
137 As per the PK evaluation, we contextualised this bias by plotting a profile produced
138 by the mean PD parameter estimates for each of the 1000 simulations, and compared
139 these to the PD profile created by the parameters used to simulate the data (Figure
140 4).

141 The ‘true’ mean initial parasite age (μ_{ipl}) was 2 hours, but had a mean estimate
142 of 2.96 hours (95% quantiles: [2.69, 3.44]). Although a seemingly large relative bias
143 (48% [34.50%, 72.0%]), this discrepancy is less than one hour difference in parasite
144 age. These still represent a mean age of parasites in the early ring stage of the parasite
145 life cycle. Estimates of the standard deviation of the initial parasite age (σ_{ipl}) are
146 associated with a similarly large relative bias (-53.3%, [-57.3%,-48.3%]). When we

147 compared the profiles produced by the estimated and ‘true’ values, (Figure 4) the
148 bias in these estimates had a negligible impact on the overall parasite dynamics.

149 The estimated values of the PD parameters representing the maximum drug effect,
150 E_{max} (‘true’ value = 0.23), and the cipargamin concentration at which half of this
151 effect is achieved, EC_{50} (‘true’ value = 15.1), have relatively moderate bias with mean
152 posterior median estimates (95% quantiles) of 0.29 (0.23, 0.38) and 17.27 (13.80,
153 21.12) ng/ml, respectively. These estimates correspond to mean relative biases of
154 26.1% for E_{max} and 14.4% for EC_{50} . These PD parameters, together with γ , define
155 the killing effect of the drug (Equation (2)). As a result, the bias in these estimates
156 produces a noticeable discrepancy in the total number of parasites post-treatment
157 (Figure 4).

158 As with the PK results, we demonstrate that this framework can recover PD
159 model parameters (excluding the mean and spread of the initial parasite age distri-
160 bution as described above) for a single experiment by presenting an example of the
161 posterior samples compared to the ‘true’ value in Figure 5. These show that the
162 true parameter values are well contained within the range of posterior samples for
163 each parameter, considering pairwise correlations. Supplementary Figure S6 shows
164 the posterior predictive PD profiles for each of the eight patients in 3 randomly se-
165 lected 8-patient cohorts, again demonstrating that the posterior model fit provides
166 an accurate characterisation of the PD profile.

3 Discussion

The results of this simulation-estimation study demonstrate that parameters of the biologically informed PK-PD model can be estimated with relatively high accuracy for Phase 2 volunteer infection studies. The PK parameters in particular were all estimated with very low bias, whereas the estimation of certain PD parameters showed comparatively less precision. In particular, the mean (μ_{ipl}) and standard deviation (σ_{ipl}) of the initial parasite age distribution corresponded to a relative bias of 48.0% and 53.3%. However, in absolute terms, this bias corresponds to approximately one hour in the 40-hour parasite life-cycle which does not substantially impact characterisation of parasite dynamics.

Post-treatment parasite counts are often below the limit of quantification (LOQ). This model accounts for the measurement uncertainty in those data points by averaging across the range $[0, \text{LOQ}]$, which provides some information on the relevant parameter values, but less than contributed by points measured above the LOQ. This imperfect observation contributes to the relatively poorer estimation performance of the PD model. Generated datasets that had more post-treatment observations under the LOQ resulted in poorer modelling accuracy (Figure S7).

This form of PK-PD Bayesian hierarchical model has been previously applied to volunteer infection and patient trial datasets [17, 18]. The mechanistic form includes the hourly age of the parasite within the red blood cell for each individual, capturing the asexual reproduction cycle of the parasite and also allowing for the inclusion of the stage specific action of the antimalarial drug. Estimates of the PK-PD model parameters can be derived using different statistical methods. Maximum likelihood methods are widely used in the analysis of data from early phase antimalarial-drug trials [9, 16]. However, these methods are limited, often failing to achieve convergence unless

192 many of the parameter values are fixed. Additionally the methods are restrictive in
193 the incorporation of pre-existing data or knowledge. In contrast, Bayesian hierar-
194 chical methods have a number of advantages, such as incorporating prior knowledge
195 or research, and allowing variation in both the population-level parameter values,
196 and the correlations between the distributions from which patient-levels values are
197 drawn.

198 Pharmaceutical research and development is a costly and time-consuming pro-
199 cess [19]. Limited understanding of drug effects can result in the waste of resources
200 though sub-optimal trial design, simultaneously diverting efforts from other candi-
201 date treatments. Therefore, careful statistical analysis and interpretation serves to
202 not only maximise the information obtained from a study, but also has the capacity
203 to reduce further inaccuracies; potentially limiting unnecessary risks for patients and
204 minimising delays in antimalarial drug development — and translation into practice.
205 In addition, further computer simulation-estimation studies can be used to determine
206 optimal sampling designs for future Phase 2 and 3 studies (*e.g.*, [20, 21]).

207 Extrapolation and applicability of these simulation results is necessarily limited
208 by the underlying assumptions of the simulation framework. This model is applied
209 with the assumption that the underlying drug and parasite dynamics are identical to
210 the form of the specified model. An area for further investigation would be evalua-
211 tion of the impact of model misspecification on recovering biological parameters via a
212 simulation-estimation study, whereby PK and/or PD dynamics are simulated under
213 a different model to that used for fitting (*e.g.*, [22]).

214 The model presented in this paper has been shown to reliably estimate the key
215 population-level PK-PD parameters within the sampling framework from a Phase 2
216 clinical trial of cipargamin [14], using simulated data. To date, there has been no
217 published formal assessment in a simulation study of the ability of a Bayesian hierar-

218 chical PK-PD model to reliably estimate model parameters in the context of malaria.
219 Therefore this paper serves as an example of model performance evaluation through
220 a simulation-estimation approach, and provides confidence in the implementation of
221 similar mechanistic malaria models and inference framework to analyse such data.
222 This flexible model can easily be adapted to study and evaluate emerging antimalar-
223 ial compounds in the future.

224 4 Methods

225 Herein we describe the pharmacokinetic (PK) and pharmacodynamic (PD) models,
226 the simulations generated from each, and the process of estimating model parameters
227 from simulated data.

228 229 **Simulation of cipargamin pharmacokinetic profiles**

230 This study simulated cipargamin concentrations using a standard two-compartment
231 first-order absorption PK model with linear elimination (Text S3 S2), as described in
232 McCarthy *et al.* [14]. The definition of each PK model parameter is given in Table
233 1. A hierarchical (or mixed-effects) model was used to account for the between- and
234 within-individual variability in cipargamin concentrations.

235 We simulated 1000 datasets, each with PK profiles for 8 patients, following the
236 sampling intervals from McCarthy *et al.* [14]. Table 3 contains the population PK
237 parameters, θ , and between-individual variability, ω , from McCarthy *et al.* [14], and
238 lower and upper bounds on each PK parameter. The bounds were chosen to allow a
239 range of feasible values spanning half to double the PK estimates from McCarthy *et*
240 *al.* [14].

241 Multiplicative error terms for individual observations were drawn from a normal
242 distribution with a mean of 0 with variance σ^2 , and exponentiated. The σ^2 value was
243 generated individually for each dataset, drawn from a log-normal distribution centred
244 at 0.1 (see Text S4 for full details)

245 246 **Pharmacodynamic Model**

247 The PD model (presented and developed in [17, 23, 18]) is a mechanistic representa-
248 tion of asexual parasite replication and death during the blood stage of the infection

249 in the presence of an anti-malarial drug, represented by a series of difference equa-
 250 tions. Representing parasite age as an integer ranging from 1 to T_{max} , the number
 251 of parasites that are a hours old at time t , $N(a, t)$, is given by the number that were
 252 $a - 1$ hours old at time $t - 1$. The only unique case is the number that are 1 hour old
 253 at $t > 0$: this is given by the number of parasites that are at the end of the life-cycle
 254 (T_{max}) at the previous time step, $N(T_{max}, t - 1)$, multiplied by the parasite multi-
 255 plication factor (PMF), representing the number of new merozoites released into the
 256 blood following the asexual reproduction of the parasite at the end of its life cycle. A
 257 stage-specific killing effect of cipargamin, $E(a, t)$, at day 7 is then applied to parasites
 258 of each age (Equation (1)). Thus, the differences equations governing the parasite
 259 distribution are:

$$N(a, t) = \begin{cases} N(a - 1, t - 1) \times (1 - E(a - 1, t - 1)), & 2 \leq a \leq T_{max} \\ N(T_{max}, t - 1) \times (1 - E(T_{max}, t - 1)) \times PMF, & a = 1. \end{cases} \quad (1)$$

260

261 Following inoculation, the initial age-distribution, $N(a, 0)$ is assumed to be normally
 262 distributed and discretised into hourly age groups. This distribution is defined by
 263 the number of parasites, ipl , and the mean, μ_{ipl} , and standard deviation, σ_{ipl} , of the
 264 parasite age distribution. During the growth phase, as the parasites age and replicate,
 265 the distribution shifts.

266 The effect of treatment on parasites of age a at time t , $E(a, t)$, is assumed to have
 267 Michaelis-Menten kinetics, and depend on the drug concentration ($C(t)$) the Maxi-
 268 mum Killing Effect (E_{max}), the drug concentration for which 50% of that maximum
 269 killing effect is achieved (EC_{50}), and lastly the sigmoidicity of the concentration-effect

270 curve (γ):

$$E(a, t) = E_{max} \frac{C(t)^\gamma}{C(t)^\gamma + EC_{50}^\gamma}, \quad E(a, t) \in [0, 1]. \quad (2)$$

271 For this model, the life cycle was set to 40h in order to enable a visual match
272 to the periodic trends of the trial data in McCarthy *et al.* [14], that were not re-
273 producible with a 48h cycle. This is consistent with Wockner *et al.* [24], where it
274 was found that a range of 38.3 to 39.2 hours was the reproductive cycle length most
275 strongly supported by their data from volunteer infection studies. Although Wock-
276 ner *et al.* were using a different parasite dynamic model, these estimates were based
277 on the same strain of malaria and a population of healthy volunteers with no prior
278 malaria infections, similar to the participants of the trial data in McCarthy *et al.* [14].

279

280 **Simulation of parasite density versus time profiles**

281 The 1000 8-patient parasite density-time datasets were simulated using the PD model,
282 each corresponding to one set of simulated PK data. Each profile begins with a
283 growth-phase starting from inoculation, followed by a treatment-phase from day 7
284 onwards. The concentration profiles of the simulated PK data were input into the
285 PD equation to generate the killing effect of the drug during treatment. Individ-
286 ual PD parameters were generated via the same approach as described for the PK
287 parameters. That is, patient-level parameters were drawn from population-level dis-
288 tributions centred around θ . Drug effect parameters were given by estimates from
289 McCarthy *et al.* [14], and the parasite multiplication factor informed by [24]. Table
290 5 contains the population PD parameters, θ , and lower and upper bounds on each
291 parameter. Aside from PK input data, the only other factors that varied between
292 simulations were the variance-covariance matrix and noise distribution.

293

294 Estimation of pharmacokinetic and pharmacodynamic parameters

295 For each of the 1000 simulated datasets, parameters were estimated in a Bayesian
296 framework using a Hamiltonian Monte Carlo No U-Turn Sampler in RStan v2.21.0
297 [25] using R version 4.1.1 [26]. For fitting the PK model to the simulated cipargamin
298 concentrations three chains were run with 2000 iterations each and 500 discarded as
299 warm-up. This produced 4500 posterior samples for each PK parameter, from which
300 the posterior median was extracted as a central estimate of the posterior distribu-
301 tion. \hat{R} , the effective sample size (n_{eff}), trace plots and posterior predictive interval
302 plots were assessed to confirm that the chains had converged and were sufficiently
303 well mixed, and that the posterior predictive distributions captured the simulated
304 cipargamin concentration profiles accurately (Figures S2 and S3).

305 For Bayesian modelling of the simulated parasitaemia data, three chains were
306 run with 1000 iterations each and 400 iterations discarded as warm-up, leaving 1800
307 for iterations for analysis. This was fewer than the number of iterations for each
308 PK dataset due to a comparatively longer processing-time to evaluate the likelihood,
309 however visual assessment of the parameter trace plots confirmed adequacy of the
310 burn-in period and suitable convergence. The same diagnostics were evaluated as for
311 the PK model fitting, in order to ensure chains were appropriately well-behaved, and
312 posterior predictive distributions characterised the data (Figure S6).

314 Graphical Representation

315 To evaluate the estimation accuracy of the PK-PD model, we compared the posterior
316 medians to the ‘true’ underlying input values. This comparison of the posteriors
317 medians (mean [95% intervals]) is presented in Tables 4 (for PK parameters) and
318 6 (PD parameters). Additionally, we plotted the hypothetical profiles that would
319 be produced by each set of posteriors median parameter values. These profiles are

320 presented in Figures 2 and 4 alongside the profile that would be produced by the true
321 population values (i.e. centres of the population parameter distributions).

322 Figures 3 and 5 present the full distribution of all posterior samples from the
323 STAN fit of a randomly selected single dataset.

324 All statistical computing code for the simulation and estimation steps is available
325 at https://github.com/M-Tully/pkpd_cipargamin_model.

Table 1: Definitions of pharmacokinetic model parameters.

Parameter (units)	Definition
Cl (L/h)	Clearance rate of the drug
V_c (L)	Central compartment volume
Q (L/h)	Inter-compartmental clearance rate
V_p (L)	Peripheral compartment volume
k_a (/h)	Absorption rate

Table 2: Definitions of pharmacodynamic model parameters.

Parameter (units)	Definition
ipl (total #)	Initial Parasite Load. Total number of parasites at inoculation or model start
μ_{ipl} (h)	Initial mean parasite age
σ_{ipl} (h)	Standard deviation of the age distribution of the initial parasite load
PMF	Parasite multiplication factor. Number of parasites released by a ruptured schizont at the end of the life cycle
E_{max} (% killed/h)	Maximal hourly killing rate of the drug
EC_{50} (ng/mL)	<i>In vivo</i> drug concentration when killing rate is 50% of E_{max}
γ	Slope of <i>in vivo</i> drug concentration-effect curve

Table 3: Population parameters (θ), and feasible lower (\mathbf{b}) and upper (\mathbf{a}) bounds for each parameter in the first-order absorption two-compartment pharmacokinetic model for cipargamin.

Parameter (units)	θ	$[\mathbf{b}, \mathbf{a}]$
Cl (L/h)	5.5	[2.75, 11]
V_c (L)	64.4	[32.2, 128.8]
Q (L/h)	12.9	[6.45, 25.8]
V_p (L)	107	[53.5, 214]
k_a (/h)	0.919	[0.460, 1.838]

Table 4: Mean PK parameter estimates [95% intervals] over 1000 fitted datasets, and associated bias when compared to the values used to simulate the data. Estimates are the posterior median values from a Bayesian hierarchical model.

Parameter (units)	'True' Value	Posterior Medians	Bias	
			Absolute	Relative (%)
Cl (L/h)	5.5	5.41 [5.08, 5.74]	-0.09 [-0.42, 0.24]	-1.64 [-7.64, 4.36]
V_c (L)	64.4	61.89 [46.52, 77.84]	-2.51 [-17.88, 13.44]	-3.90 [-27.76, 20.87]
Q (L/h)	12.9	12.36 [10.12, 14.40]	-0.54 [-2.78, 1.50]	-4.19 [-21.55, 11.63]
V_p (L)	107	111.44 [89.13, 139.44]	4.44 [-17.87, 32.44]	4.15 [-16.70, 30.32]
k_a (/h)	0.919	0.996 [0.83, 1.21]	0.08 [-0.09, 0.29]	8.38 [-9.68, 31.66]

Table 5: Population parameters (θ), and feasible lower (\mathbf{b}) and upper (\mathbf{a}) bounds for each parameter in the pharmacodynamic model.

Parameter (units)	θ	$[\mathbf{b}, \mathbf{a}]$
i_{pl} (total #)	1800	[1500, 2100]
μ_{ipl} (h)	2	[1, 24]
σ_{ipl} (h)	3	[1, 14]
PMF	13	[5, 50]
E_{max} (% killed/h)	0.23	[0.05, 1]
EC_{50} (ng/mL)	15.1	[0.5, 30]
γ	5	[0.05, 1.838]

Table 6: Mean PD parameter estimates [95% intervals] over 1000 fitted datasets, and associated bias when compared to the values used to simulate the data. Estimates are the posterior median values from a Bayesian hierarchical model.

Parameter (units)	'True' Value	Posterior Medians	Bias	
			Absolute	Relative (%)
ipl ($\# \times 10^3$)	1.8	1.78 [1.75, 1.82]	-0.02 [-0.051, 0.018]	-1.11 [-2.83, 1.00]
μ_{ipl} (h)	2	2.96 [2.69, 3.44]	0.96 [0.69, 1.44]	48.00 [34.50, 72.00]
σ_{ipl} (h)	3	1.40 [1.28, 1.55]	-1.60 [-1.72, -1.45]	-53.33 [-57.33, -48.33]
PMF	13	14.55 [13.48, 16.80]	1.55 [0.48, 3.80]	11.92 [3.69, 29.23]
E_{max} (% killed/h)	0.23	0.29 [0.23, 0.38]	0.06 [0.00, 0.15]	26.09 [0.00, 65.22]
EC_{50} (ng/mL)	15.1	17.27 [13.80, 21.12]	2.17 [-1.30, 6.02]	14.37 [-8.61, 39.87]
γ	5	4.72 [2.86, 6.83]	-0.28 [-2.14, 1.83]	-5.60 [-42.80, 36.60]




Figure 1: Flowchart describing the stages of the current simulation study framework.




Figure 2: PK drug concentration profiles for a 2-compartment model produced from 'true' parameters values used in creating the simulations (black), compared to 1000 profiles created from each of the 1000 dataset's mean estimated values (grey).




Figure 3: Bivariate distributions of posterior samples for population-level PK parameters, from the STAN fit of a single simulated dataset. Red dots indicate ‘true’ underlying parameter values used to simulate data.




Figure 4: PD parasite profiles produced from ‘true’ parameters values used to create the simulations (black), compared to 1000 profiles created from each of the 1000 dataset’s mean estimated parameter values (grey). Dashed vertical line at day 7 indicates treatment.




Figure 5: Bivariate distributions of posterior samples for population-level PD parameters, from the STAN fit of a single simulated dataset. Red dots indicate ‘true’ underlying parameter values used to simulate data.

References

- [1] World Health Organization; 2023. *Geneva: World malaria report 2023*. Geneva.
- [2] E. A. Ashley et al. “Spread of artemisinin resistance in *Plasmodium falciparum* malaria”. In: *N Engl J Med* 371.5 (2014), pp. 411–23. ISSN: 1533-4406 (Electronic) 0028-4793 (Print) 0028-4793 (Linking). DOI: 10.1056/NEJMoa1314981. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25075834>.
- [3] B. Balikagala et al. “Evidence of Artemisinin-Resistant Malaria in Africa”. In: *N Engl J Med* 385.13 (2021), pp. 1163–1171. ISSN: 1533-4406 (Electronic) 0028-4793 (Linking). DOI: 10.1056/NEJMoa2101746. URL: <https://www.ncbi.nlm.nih.gov/pubmed/34551228>.
- [4] A. Uwimana et al. “Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda”. In: *Nat Med* 26.10 (2020), pp. 1602–1608. ISSN: 1078-8956 (Print) 1078-8956. DOI: 10.1038/s41591-020-1005-2.
- [5] Luana C. Mathieu et al. “Local emergence in Amazonia of *Plasmodium falciparum* k13 C580Y mutants associated with in vitro artemisinin resistance”. In: *eLife* 9 (2020), e51015. ISSN: 2050-084X. DOI: 10.7554/eLife.51015. URL: <https://doi.org/10.7554/eLife.51015>.
- [6] O. Miotto et al. “Emergence of artemisinin-resistant *Plasmodium falciparum* with kelch13 C580Y mutations on the island of New Guinea”. In: *PLoS Pathog* 16.12 (2020), e1009133. ISSN: 1553-7366 (Print) 1553-7366. DOI: 10.1371/journal.ppat.1009133.
- [7] V. Duru, B. Witkowski, and D. Menard. “*Plasmodium falciparum* Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria

- 351 Elimination in Cambodia”. In: *Am J Trop Med Hyg* 95.6 (2016), pp. 1228–1238.
352 ISSN: 1476-1645 (Electronic) 0002-9637 (Linking). DOI: 10.4269/ajtmh.16-
353 0234. URL: <https://www.ncbi.nlm.nih.gov/pubmed/27928074>.
- 354 [8] M. Hay et al. “Clinical development success rates for investigational drugs”. In:
355 *Nat Biotechnol* 32.1 (2014), pp. 40–51. ISSN: 1546-1696 (Electronic) 1087-0156
356 (Linking). DOI: 10.1038/nbt.2786. URL: [https://www.ncbi.nlm.nih.gov/
357 pubmed/24406927](https://www.ncbi.nlm.nih.gov/pubmed/24406927).
- 358 [9] A. N. Abd-Rahman et al. “Scoping Review of Antimalarial Drug Candidates
359 in Phase I and II Drug Development”. In: *Antimicrob Agents Chemother* 66.2
360 (2022), e0165921. ISSN: 0066-4804 (Print) 0066-4804. DOI: 10.1128/aac.01659-
361 21.
- 362 [10] S. A. Bouwman et al. “The early preclinical and clinical development of cipargamin
363 (KAE609), a novel antimalarial compound”. In: *Travel Med Infect Dis* 36 (2020),
364 p. 101765. ISSN: 1873-0442 (Electronic) 1477-8939 (Linking). DOI: 10.1016/j.
365 tmaid.2020.101765. URL: [https://www.ncbi.nlm.nih.gov/pubmed/
366 32561392](https://www.ncbi.nlm.nih.gov/pubmed/32561392).
- 367 [11] E. K. Schmitt et al. “Efficacy of Cipargamin (KAE609) in a Randomized, Phase
368 II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated
369 Plasmodium falciparum Malaria”. In: *Clin Infect Dis* 74.10 (2022), pp. 1831–
370 1839. ISSN: 1537-6591 (Electronic) 1058-4838 (Linking). DOI: 10.1093/cid/
371 ciab716. URL: <https://www.ncbi.nlm.nih.gov/pubmed/34410358>.
- 372 [12] G. Ndayisaba et al. “Hepatic safety and tolerability of cipargamin (KAE609),
373 in adult patients with Plasmodium falciparum malaria: a randomized, phase
374 II, controlled, dose-escalation trial in sub-Saharan Africa”. In: *Malar J* 20.1
375 (2021), p. 478. ISSN: 1475-2875. DOI: 10.1186/s12936-021-04009-1.

- 376 [13] N. J. White et al. “Spiroindolone KAE609 for falciparum and vivax malaria”.
377 In: *N Engl J Med* 371.5 (2014). 1533-4406 White, Nicholas J Pukrittayakamee,
378 Sasithon Phyo, Aung Pyae Rueangweerayut, Ronnatrai Nosten, François Jit-
379 tamala, Podjanee Jeeyapant, Atthanee Jain, Jay Prakash Lefèvre, Gilbert Li,
380 Ruobing Magnusson, Baldur Diagana, Thierry T Leong, F Joel Wellcome Trust/United
381 Kingdom 077166/Wellcome Trust/United Kingdom 093956/Wellcome Trust/United
382 Kingdom 096157/Wellcome Trust/United Kingdom Clinical Trial, Phase II Jour-
383 nal Article Multicenter Study Research Support, Non-U.S. Gov’t United States
384 2014/07/31 N Engl J Med. 2014 Jul 31;371(5):403-10. doi: 10.1056/NEJMoa1315860.,
385 pp. 403–10. ISSN: 0028-4793 (Print) 0028-4793. DOI: 10.1056/NEJMoa1315860.
- 386 [14] J. S. McCarthy et al. “Defining the Antimalarial Activity of Cipargamin in
387 Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium fal-
388 ciparum”. In: *Antimicrobial agents and chemotherapy* 65.2 (2021), e01423–20.
389 ISSN: 1098-6596 0066-4804. DOI: 10.1128/AAC.01423-20. URL: [https://](https://pubmed.ncbi.nlm.nih.gov/33199389)
390 pubmed.ncbi.nlm.nih.gov/33199389[https://www.ncbi.nlm.nih.gov/pmc/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849011/)
391 [articles/PMC7849011/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849011/).
- 392 [15] D. I. Staniscic, J. S. McCarthy, and M. F. Good. “Controlled Human Malaria In-
393 fection: Applications, Advances, and Challenges”. In: *Infect Immun* 86.1 (2018).
394 ISSN: 1098-5522 (Electronic) 0019-9567 (Print) 0019-9567 (Linking). DOI: 10.
395 1128/IAI.00479-17. URL: [https://www.ncbi.nlm.nih.gov/pubmed/](https://www.ncbi.nlm.nih.gov/pubmed/28923897)
396 [28923897](https://www.ncbi.nlm.nih.gov/pubmed/28923897).
- 397 [16] J. A. Simpson et al. “Making the most of clinical data: reviewing the role of
398 pharmacokinetic-pharmacodynamic models of anti-malarial drugs”. In: *Aaps j*
399 16.5 (2014). 1550-7416 Simpson, Julie A Zaloumis, Sophie DeLivera, Alysha M
400 Price, Ric N McCaw, James M 091625/Wellcome Trust/United Kingdom Jour-

- 401 nal Article Research Support, Non-U.S. Gov't Review United States 2014/07/25
402 AAPS J. 2014 Sep;16(5):962-74. doi: 10.1208/s12248-014-9647-y. Epub 2014 Jul
403 24., pp. 962–74. ISSN: 1550-7416. DOI: 10.1208/s12248-014-9647-y.
- 404 [17] S. Dini et al. “Seeking an optimal dosing regimen for OZ439/DSM265 combi-
405 nation therapy for treating uncomplicated falciparum malaria”. In: *Journal of*
406 *Antimicrobial Chemotherapy* 76.9 (2021), pp. 2325–2334. ISSN: 0305-7453. DOI:
407 10.1093/jac/dkab181. URL: <https://doi.org/10.1093/jac/dkab181>.
- 408 [18] S. Zaloumis et al. “Assessing the utility of an anti-malarial pharmacokinetic-
409 pharmacodynamic model for aiding drug clinical development”. In: *Malar J*
410 11 (2012), p. 303. ISSN: 1475-2875 (Electronic) 1475-2875 (Linking). DOI: 10.
411 1186/1475-2875-11-303. URL: [https://www.ncbi.nlm.nih.gov/pubmed/](https://www.ncbi.nlm.nih.gov/pubmed/22931058)
412 22931058.
- 413 [19] K. Smietana, M. Siatkowski, and M. Moller. “Trends in clinical success rates”.
414 In: *Nat Rev Drug Discov* 15.6 (2016), pp. 379–80. ISSN: 1474-1784 (Electronic)
415 1474-1776 (Linking). DOI: 10.1038/nrd.2016.85. URL: [https://www.ncbi.](https://www.ncbi.nlm.nih.gov/pubmed/27199245)
416 [nlm.nih.gov/pubmed/27199245](https://www.ncbi.nlm.nih.gov/pubmed/27199245).
- 417 [20] Kris M. Jansen et al. “Optimal designs for population pharmacokinetic stud-
418 ies of the partner drugs co-administered with artemisinin derivatives in pa-
419 tients with uncomplicated falciparum malaria”. In: *Malaria Journal* 11.1 (2012),
420 p. 143.
- 421 [21] Jennifer A. Flegg et al. “Optimal sampling designs for estimation of Plasmodium
422 falciparum clearance rates in patients treated with artemisinin derivatives”. In:
423 *Malaria Journal* 12.1 (2013), p. 411. DOI: 10.1186/1475-2875-12-411. URL:
424 <https://doi.org/10.1186/1475-2875-12-411>.

- 425 [22] David J. Nott, Christopher Drovandi, and David T. Frazier. “Bayesian Infer-
426 ence for Misspecified Generative Models”. In: *Annual Review of Statistics and*
427 *Its Application* (2023). ISSN: 2326-8298. DOI: [https://doi.org/10.1146/](https://doi.org/10.1146/annurev-statistics-040522-015915)
428 [annurev-statistics-040522-015915](https://doi.org/10.1146/annurev-statistics-040522-015915). URL: [https://www.annualreviews.](https://www.annualreviews.org/content/journals/10.1146/annurev-statistics-040522-015915)
429 [org/content/journals/10.1146/annurev-statistics-040522-015915](https://www.annualreviews.org/content/journals/10.1146/annurev-statistics-040522-015915).
- 430 [23] S. Saralamba et al. “Intrahost modeling of artemisinin resistance in *Plasmodium*
431 *falciparum*”. In: *Proceedings of the National Academy of Sciences* 108.1 (2010),
432 pp. 397–402. ISSN: 0027-8424 1091-6490. DOI: 10.1073/pnas.1006113108.
- 433 [24] L. F. Wockner et al. “Growth Rate of *Plasmodium falciparum*: Analysis of Par-
434 asite Growth Data From Malaria Volunteer Infection Studies”. In: *J Infect Dis*
435 221.6 (2020), pp. 963–972. ISSN: 1537-6613 (Electronic) 0022-1899 (Linking).
436 DOI: 10.1093/infdis/jiz557. URL: [https://www.ncbi.nlm.nih.gov/](https://www.ncbi.nlm.nih.gov/pubmed/31679015)
437 [pubmed/31679015](https://www.ncbi.nlm.nih.gov/pubmed/31679015).
- 438 [25] Stan Development Team. *Stan Modeling Language Users Guide and Reference*
439 *Manual*. Version 2.21.0. 2021. URL: <https://mc-stan.org>.
- 440 [26] R Core Team. *R: A Language and Environment for Statistical Computing*. Ver-
441 sion 4.1.1. R Foundation for Statistical Computing. Vienna, Austria, 2021. URL:
442 <https://www.R-project.org/>.